339 related articles for article (PubMed ID: 28986164)
21. Rosiglitazone improves exercise capacity in individuals with type 2 diabetes.
Regensteiner JG; Bauer TA; Reusch JE
Diabetes Care; 2005 Dec; 28(12):2877-83. PubMed ID: 16306548
[TBL] [Abstract][Full Text] [Related]
22. Diabetes and branched-chain amino acids: What is the link?
Bloomgarden Z
J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
[TBL] [Abstract][Full Text] [Related]
23. Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.
Karlsson HK; Hällsten K; Björnholm M; Tsuchida H; Chibalin AV; Virtanen KA; Heinonen OJ; Lönnqvist F; Nuutila P; Zierath JR
Diabetes; 2005 May; 54(5):1459-67. PubMed ID: 15855334
[TBL] [Abstract][Full Text] [Related]
24. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients.
Negro R; Mangieri T; Dazzi D; Pezzarossa A; Hassan H
Diabetes Res Clin Pract; 2005 Oct; 70(1):20-5. PubMed ID: 16126119
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
Virtanen KA; Hällsten K; Parkkola R; Janatuinen T; Lönnqvist F; Viljanen T; Rönnemaa T; Knuuti J; Huupponen R; Lönnroth P; Nuutila P
Diabetes; 2003 Feb; 52(2):283-90. PubMed ID: 12540598
[TBL] [Abstract][Full Text] [Related]
26. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
[TBL] [Abstract][Full Text] [Related]
27. [Effects of rosiglitazone on endothelium-dependent vasodilation in patients with Type 2 diabetes].
Wu J; Lei MX; Liu L; Huang YJ
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Aug; 31(4):570-4. PubMed ID: 16951521
[TBL] [Abstract][Full Text] [Related]
28. The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects.
James AP; Watts GF; Mamo JC
Diabetes Obes Metab; 2005 Jul; 7(4):381-9. PubMed ID: 15955124
[TBL] [Abstract][Full Text] [Related]
29. A novel index of insulin resistance determined from the homeostasis model assessment index and adiponectin levels in Japanese subjects.
Matsuhisa M; Yamasaki Y; Emoto M; Shimabukuro M; Ueda S; Funahashi T; Matsuzawa Y
Diabetes Res Clin Pract; 2007 Jul; 77(1):151-4. PubMed ID: 17081646
[TBL] [Abstract][Full Text] [Related]
30. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
31. Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin.
Viljanen AP; Virtanen KA; Järvisalo MJ; Hällsten K; Parkkola R; Rönnemaa T; Lönnqvist F; Iozzo P; Ferrannini E; Nuutila P
J Clin Endocrinol Metab; 2005 Dec; 90(12):6523-8. PubMed ID: 16189256
[TBL] [Abstract][Full Text] [Related]
32. Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD.
Lin SH; Lin YF; Kuo SW; Hsu YJ; Hung YJ
Am J Kidney Dis; 2003 Oct; 42(4):774-80. PubMed ID: 14520628
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment.
Ikeda Y; Suehiro T; Nakamura T; Kumon Y; Hashimoto K
Endocr J; 2001 Feb; 48(1):81-6. PubMed ID: 11403106
[TBL] [Abstract][Full Text] [Related]
34. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.
Hung YJ; Lin SH; Pei D; Kuo SW; Hsieh CH; He CT; Hsing Lee C; Fan SC; Sheu WH
Metabolism; 2006 Apr; 55(4):439-44. PubMed ID: 16546473
[TBL] [Abstract][Full Text] [Related]
35. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Henry RR
Clin Ther; 2003; 25 Suppl B():B47-63. PubMed ID: 14553866
[TBL] [Abstract][Full Text] [Related]
36. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment are useful indexes of insulin resistance in type 2 diabetic patients with wide range of fasting plasma glucose.
Yokoyama H; Emoto M; Fujiwara S; Motoyama K; Morioka T; Komatsu M; Tahara H; Koyama H; Shoji T; Inaba M; Nishizawa Y
J Clin Endocrinol Metab; 2004 Mar; 89(3):1481-4. PubMed ID: 15001651
[TBL] [Abstract][Full Text] [Related]
37. [Insulin sensitivity in vivo: evaluation of non insulin dependent diabetes mellitus patients and healthy subjects by euglycemic hyperinsulinemic clamp].
Calvillán M; Durruty P; López G; Rocha G
Rev Med Chil; 1991 Oct; 119(10):1101-8. PubMed ID: 1845203
[TBL] [Abstract][Full Text] [Related]
38. Obesity, type 2 diabetes, and impaired insulin-stimulated blood flow: role of skeletal muscle NO synthase and endothelin-1.
Reynolds LJ; Credeur DP; Manrique C; Padilla J; Fadel PJ; Thyfault JP
J Appl Physiol (1985); 2017 Jan; 122(1):38-47. PubMed ID: 27789766
[TBL] [Abstract][Full Text] [Related]
39. The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin.
Kashi Z; Masoumi P; Mahrooz A; Hashemi-Soteh MB; Bahar A; Alizadeh A
Diabetes Res Clin Pract; 2015 Apr; 108(1):78-83. PubMed ID: 25662675
[TBL] [Abstract][Full Text] [Related]
40. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas.
Emoto M; Nishizawa Y; Maekawa K; Hiura Y; Kanda H; Kawagishi T; Shoji T; Okuno Y; Morii H
Diabetes Care; 1999 May; 22(5):818-22. PubMed ID: 10332688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
